Department of Cell Biology, Laboratory for Clinical Medicine, Municipal Laboratory for Liver Protection and Regulation of Regeneration, Capital Medical University, No. 10 Xitoutiao, You An Men, Beijing, 100069, China.
J Mol Med (Berl). 2024 Sep;102(9):1117-1133. doi: 10.1007/s00109-024-02469-x. Epub 2024 Jul 12.
Fatty liver, which is induced by abnormal lipid metabolism, is one of the most common causes of chronic liver disease globally and causes liver fibrosis. During this process, bone marrow-derived mesenchymal stromal cells (BMSCs) and hepatic stellate cells (HSCs) migrate toward the injured liver and participate in fibrogenesis by transdifferentiating into myofibroblasts. S100A8/A9 is a powerful inducer of cell migration and is involved in liver injury. But there are few reports about the effects of S100A8/A9 on BMSC/HSC migration. In the current study, we found that S100A8/A9 expression was increased during fatty liver injury/fibrogenesis. Moreover, S100A8/A9 expression had a positive correlation with fibrosis marker gene expressions in the injured liver. S100A8/A9 was mainly produced by neutrophils in the fibrotic liver. In vitro, neutrophil-secreted S100A8/A9 promoted BMSC/HSC migration via remodeling of microfilaments. Using specific siRNA and inhibitor, we proved that S100A8/A9-induced BMSC/HSC migration is dependent on TLR4/Rho GTPases signaling. Moreover, S100A8/A9 knock-down alleviated liver injury and fibrogenesis in vivo, while injection of S100A9 neutralizing antibody performed similar roles. We proved that S100A8/A9 was involved in liver injury and fibrogenesis via inducing BMSC/HSC migration. Our research reveals a new mechanism underlying BMSC/HSC migration in liver fibrosis and suggests S100A8/A9 as a potential therapeutic target of liver fibrosis. KEY MESSAGES: S100A8/A9 is secreted by neutrophils and increased in fatty liver injury. Neutrophil-secreted S100A8/A9 is a mediator of BMSC/HSC migration in vitro. S100A8/A9-induced BMSC/HSC migration is dependent on TLR4/Rho GTPases signaling. S100A8/A9 blockade alleviates liver injury and fibrogenesis in vivo.
脂肪肝是由脂质代谢异常引起的,是全球最常见的慢性肝病病因之一,可导致肝纤维化。在这个过程中,骨髓间充质基质细胞(BMSCs)和肝星状细胞(HSCs)向受损的肝脏迁移,并通过转分化为肌成纤维细胞参与纤维化形成。S100A8/A9 是细胞迁移的强大诱导剂,参与肝损伤。但是,关于 S100A8/A9 对 BMSC/HSC 迁移的影响的报道很少。在本研究中,我们发现 S100A8/A9 在脂肪肝损伤/纤维化过程中表达增加。此外,S100A8/A9 的表达与受损肝脏中纤维化标记基因的表达呈正相关。S100A8/A9 主要由纤维化肝脏中的中性粒细胞产生。在体外,中性粒细胞分泌的 S100A8/A9 通过重塑微丝促进 BMSC/HSC 迁移。使用特异性 siRNA 和抑制剂,我们证明 S100A8/A9 诱导的 BMSC/HSC 迁移依赖于 TLR4/Rho GTPases 信号通路。此外,S100A8/A9 敲低可减轻体内肝损伤和纤维化,而注射 S100A9 中和抗体可发挥类似作用。我们证明 S100A8/A9 通过诱导 BMSC/HSC 迁移参与肝损伤和纤维化。我们的研究揭示了肝纤维化中 BMSC/HSC 迁移的新机制,并表明 S100A8/A9 可能是肝纤维化的潜在治疗靶点。关键信息:S100A8/A9 由中性粒细胞分泌,在脂肪肝损伤中增加。中性粒细胞分泌的 S100A8/A9 是体外 BMSC/HSC 迁移的介质。S100A8/A9 诱导的 BMSC/HSC 迁移依赖于 TLR4/Rho GTPases 信号通路。S100A8/A9 阻断可减轻体内肝损伤和纤维化。